Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Respiratory syncytial virus vaccine adjuvanted - GSK

Next Previous
X
Search
Drug Profile

Respiratory syncytial virus vaccine adjuvanted - GSK

Alternative Names: AREXVY; Arexvy; GSK-3844766; GSK-3844766A; Respiratory syncytial virus vaccine, adjuvanted - GlaxoSmithKline; RSV vaccine, Adjuvanted - GSK; RSV_PreF3 Vaccine; RSVPreF3 OA; RSVPreF3 OA vaccine

Latest Information Update: 20 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Respiratory syncytial virus vaccines; Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Respiratory syncytial virus infections

Most Recent Events

  • 05 Aug 2024 Phase-III clinical trials in Respiratory syncytial virus infections (In adults, In the elderly, Prevention) in Spain (IM) (NCT06551181)
  • 05 Aug 2024 GlaxoSmithKline initiates a phase III trial for Respiratory syncytial virus infections (In adults, In the elderly, Prevention) in the United Kingdom (IM) (NCT06551181)
  • 01 Aug 2024 Phase-III clinical trials in Respiratory syncytial virus infections (In the elderly, Prevention) in USA, Japan (IM) (NCT06534892)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top